Scarica l'app Stockscreener
8.11
1.76%
0.14
Dopo l'orario di chiusura:
8.11
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché TNGX Giù?
Forum
Previsione
Precedente Chiudi:
$7.97
Aprire:
$7.97
Volume 24 ore:
2.55M
Relative Volume:
0.95
Capitalizzazione di mercato:
$902.32M
Reddito:
$24.30M
Utile/perdita netta:
$-145.57M
Rapporto P/E:
-6.0977
EPS:
-1.33
Flusso di cassa netto:
$-149.17M
1 W Prestazione:
+8.21%
1M Prestazione:
-3.45%
6M Prestazione:
+475.18%
1 anno Prestazione:
+49.22%
Intervallo 1D:
$7.83
$8.35
Intervallo di 1 settimana:
$7.12
$8.35
Portata 52W:
$1.03
$9.70
Tango Therapeutics Inc Stock (TNGX) Company Profile
Nome
Tango Therapeutics Inc
Settore
Industria
Telefono
(857) 320-4900
Indirizzo
201 BROOKLINE AVENUE, BOSTON
Confronta TNGX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
TNGX
Tango Therapeutics Inc
|
8.11 | 1.05B | 24.30M | -145.57M | -149.17M | -1.33 |
|
VRTX
Vertex Pharmaceuticals Inc
|
425.57 | 107.66B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
651.80 | 68.74B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
456.04 | 58.93B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
818.50 | 50.51B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
189.60 | 41.29B | 447.02M | -1.18B | -868.57M | -6.1812 |
Tango Therapeutics Inc Stock (TNGX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-08-19 | Iniziato | Piper Sandler | Overweight |
| 2024-07-17 | Iniziato | Jefferies | Buy |
| 2024-04-04 | Iniziato | Cantor Fitzgerald | Overweight |
| 2024-02-12 | Iniziato | Piper Sandler | Overweight |
| 2023-12-08 | Iniziato | B. Riley Securities | Buy |
| 2022-10-20 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
| 2021-09-20 | Iniziato | SVB Leerink | Outperform |
Mostra tutto
Tango Therapeutics Inc Borsa (TNGX) Ultime notizie
Short interest data insights for Tango Therapeutics Inc.2025 AllTime Highs & Technical Analysis for Trade Confirmation - newser.com
Long term hold vs stop loss in Tango Therapeutics Inc.Portfolio Risk Summary & Comprehensive Market Scan Reports - newser.com
Does Tango Therapeutics Inc. fit your quant trading model2025 EndofYear Setup & Risk Managed Investment Signals - newser.com
Tango Therapeutics Inc. stock trend outlook and recovery pathIndex Update & Low Volatility Stock Recommendations - newser.com
Wall Street Analysts Think Tango Therapeutics (TNGX) Could Surge 52.2%: Read This Before Placing a Bet - sharewise.com
Why Protagonist Therapeutics Stock Skyrocketed by Almost 30% Today - AOL.com
Why Tango Therapeutics Inc. stock is trending among retail tradersJuly 2025 Volume & Capital Efficient Trading Techniques - newser.com
What is HC Wainwright's Estimate for TNGX FY2026 Earnings? - MarketBeat
Is Tango Therapeutics Inc. stock entering bullish territoryMarket Movers & Consistent Growth Equity Picks - newser.com
How to build a dashboard for Tango Therapeutics Inc. stock2025 Trade Ideas & Expert Verified Stock Movement Alerts - newser.com
Will Tango Therapeutics Inc. stock maintain dividend yield2025 Price Action Summary & Safe Entry Zone Tips - newser.com
Multi asset correlation models including Tango Therapeutics Inc.Market Growth Review & High Conviction Investment Ideas - newser.com
Is Tango Therapeutics Stock a Buy, Sell, or Hold After Major Shareholder Third Rock Ventures Sold Nearly Half a Million Shares? - Mitrade
Ranking Tango Therapeutics Inc. among high performing stocks via toolsJuly 2025 Earnings & Entry and Exit Point Strategies - newser.com
Tango Therapeutics price target raised to $12 from $10 at Guggenheim - MSN
Tango Therapeutics’ Promising Update on TNG260 Clinical Study - MSN
TNGX FY2025 EPS Forecast Boosted by Cantor Fitzgerald - MarketBeat
Revolution Medicines and Tango Therapeutics Advance in Targeted Cancer Therapy Study - MSN
Tango Therapeutics (TNGX) Expected to Announce Earnings on Wednesday - MarketBeat
Tango Therapeutics Inc. (TNGX) Stock Price | Live Quotes & Charts | NSD - StocksToTrade
Tango Therapeutics Advances Innovative Cancer Treatment with S095035 Clinical Trial - TipRanks
Why Tango Therapeutics (TNGX) Surged After Positive Vopimetostat Trial Results and Major Capital Raise - Yahoo Finance
Tango Therapeutics to Report Third Quarter 2025 Financial Results on Tuesday, November 4, 2025 - The Manila Times
Tango (NASDAQ: TNGX) will report third quarter results Nov 4; no conference call - Stock Titan
Tango Therapeutics (TNGX) Price Target Increased by 11.49% to 12.37 - Nasdaq
Tango Therapeutics Stock Fell 15% in a Week, What Now? - Trefis
Will Tango Therapeutics Inc. stock remain a Wall Street favoriteJuly 2025 Spike Watch & Free Verified High Yield Trade Plans - fcp.pa.gov.br
Tango Therapeutics (TNGX) Upgraded to Buy: Here's Why - sharewise.com
Using AI based signals to follow Tango Therapeutics Inc.Market Risk Report & AI Enhanced Execution Alerts - newser.com
TNGX insider sale: 477,401 shares at $10.00–$10.65 range - Stock Titan
Tango Therapeutics Advances TNG462 Study for MTAP-deleted Tumors - TipRanks
Tango Therapeutics Inc Azioni (TNGX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.62%
0.21%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):